Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oxygen hires PFC Pharma for Phase II traumatic brain injury trials
The company has initiated the filing process for their protocol in Switzerland with the relevant cantonal ethic committees and Swissmedic, the Swiss counterpart to the US FDA. This
The company has initiated the filing process for their protocol in Switzerland with the relevant cantonal ethic committees and Swissmedic, the Swiss counterpart to the US FDA. This
The Data Safety Monitoring Board (DSMB) meets every six months to review unblinded safety data from the toremifene Phase III clinical trials. Nearly 1,600 patients with high grade
Under the terms of the agreement, PharmaForm will develop products in one or more therapeutic areas utilizing PharmaForm’s core expertise in hot melt extrusion. In addition to providing
The new Yokohama facility is the single largest combined Bruker applications laboratory in the world, showcasing a selection of novel life science, materials research and industrial systems including
During this study, 41 out of the 43 patients treated showed a positive response to treatment. Serenity has also completed an end-of-Phase-II meeting with the FDA. John Sedor,
The BD Soluvia microinjection system offers a reliable method of intradermal delivery, which integrates a 1.5mm length BD microneedle with a 0.1ml injected volume. As a prefillable delivery
Prior to joining Illumina, Mr Flatley was president and CEO of Molecular Dynamics, now part of GE Healthcare, and led that company’s initial public offering in 1993. Mr
According to Genzyme, Synvisc-One is the only single-injection viscosupplement approved for the treatment of osteoarthritis knee pain in the US. It is also approved in the EU and
Cypress said that the acquisition is consistent with its strategy of providing innovative products and services that address unmet medical needs in the fields of rheumatology and pain.
The funding will advance the company’s lead program targeted against NS4B, a specific region in the hepatitis C virus protein. David Cory, president and CEO of Eiger, said: